Incremental value of copeptin to highly sensitive cardiac Troponin i for rapid rule-out of myocardial infarction
Abstract
Background: The incremental value of copeptin, a novel marker of endogenous stress, for rapid rule-out of non- ST-elevation myocardial infarction (NSTEMI) is unclear when sensitive or even high-sensitivity cardiac troponin cTn (hs-cTn) assays are used. Methods: In an international multicenter study we evaluated 1929 consecutive patients with symptoms suggestive of acute myocardial infarction (AMI). Measurements of copeptin, three sensitive and three hs-cTn assays were performed at presentation in a blinded fashion. The final diagnosis was adjudicated by two independent cardiologists using all clinical information including coronary angiography and levels of hs-cTnT. The incremental value in the diagnosis of NSTEMIwas quantified using four outcomemeasures: area under the receiver-operating characteristic curve (AUC), integrated discrimination improvement (IDI), sensitivity and negative predictive value (NPV). Early presenters (b4 h since chest pain onset) were a pre-defined subgroup. Results: NSTEMI was the adjudicated final diagnosis in 358 (18.6%) patients. As compared to the use of cTn alone, copeptin significantly increased AUC for two (33%) and IDI (between 0.010 and 0.041 (all p b 0.01)), sensitivity and NPV for all six cTn assays (100%); NPV to 96-99% when the 99th percentile of the respective cTnI assay was combinedwith a copeptin level of 9 pmol/l (all p b 0.01). The incremental value in early presenterswas similar to that of the overall cohort. Conclusion: When used for rapid rule-out of NSTEM in combination with sensitive or hs-cTnI assays, copeptin provides a numerically small, but statistically and likely also clinically significant incremental value.
Bibliografische Daten
Originalsprache | Englisch |
---|---|
ISSN | 0167-5273 |
DOIs | |
Status | Veröffentlicht - 01.07.2015 |
Extern publiziert | Ja |
Anmerkungen des Dekanats
Funding Information:
This study was supported by research grants from the Swiss National Science Foundation ( PP00B-102853 ), the Swiss Heart Foundation , the University Basel , Abbott , BRAHMS , Roche , Siemens , and the Department of Internal Medicine, University Hospital Basel .
Funding Information:
Dr. Mueller has received research grants from the Swiss National Science Foundation (PP00B-102853) and the Swiss Heart Foundation, Abbott, Alere, Beckman Coulter, BRAHMS, Critical Diagnostics, Nanosphere, Roche, Siemens, Singulex, 8sense, and the Department of Internal Medicine, of the University Hospital Basel, as well as a speaker/consulting honoraria from Abbott, Alere, Biomerieux, BRAHMS, Cardiorentis, Novartis, Roche, Siemens, and Singulex. We disclose that Dr. Reichlin has received research grants from the Swiss National Science Foundation ( PASMP3-136995 ), the Swiss Heart Foundation, the University of Basel, the Professor Max Cloetta Foundation and the Department of Internal Medicine, University Hospital Basel as well as a speaker's honoraria from BRAHMS and Roche. All other authors declare that they have no conflict of interest with this study. The assays were provided by the manufacturers, who had no influence on the design of the study, the analysis of the data, the preparation of the manuscript, or the decision to submit the manuscript for publication. All authors fulfill the criteria for authorship and have approved the final article.
Publisher Copyright:
© 2015 Elsevier Ireland Ltd. All rights reserved.